GlassScriptPhysician profile
Robert L Talley
NPI 1124091384
$2,513.91
in general payments reported to CMS, 2019-2025
30 companies · $337 in 2025
The $337 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.42 · 2020: $22.49 · 2021: $409 · 2022: $824 · 2023: $619 · 2024: $288 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $434.36 | 2021-2022 | |
| Novocure INC. | $353.51 | 2021-2025 | Optune Lua (Novottf-200t) |
| Novartis Pharmaceuticals Corporation | $269.59 | 2020-2023 | |
| Pfizer INC. | $227.60 | 2022-2024 | |
| Array Biopharma INC | $130.04 | 2022-2024 | Braftovi, Mektovi, Lorbrena |
| Takeda Pharmaceuticals U.S.A., INC. | $117.08 | 2022-2024 | Advate, Iclusig |
| Janssen Biotech, INC. | $99.49 | 2019-2023 | Erleada |
| Gilead Sciences, INC. | $90.27 | 2021-2023 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $89.71 | 2023-2024 | Libtayo |
| Genentech USA, INC. | $87.67 | 2023-2024 | Lunsumio, Polivy, Columvi |
| Celgene Corporation | $79.10 | 2022-2023 | Reblozyl, Opdualag |
| Kite Pharma, INC. | $63.57 | 2021-2022 | |
| Eisai INC. | $61.55 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $59.50 | 2023 | Epkinly, Imbruvica |
| Abbvie INC. | $45.25 | 2023-2024 | Venclexta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $32.59 | 2022-2023 | Opdualag |
| Astrazeneca Pharmaceuticals LP | $31.68 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.71 | 2021 | |
| Glaxosmithkline, LLC. | $24.44 | 2022 | |
| Astellas Pharma US INC | $24.18 | 2023 | Padcev |
| Ipsen Biopharmaceuticals, INC | $20.01 | 2023 | Tazverik |
| Incyte Corporation | $19.63 | 2023 | Jakafi |
| Puma Biotechnology, INC. | $19.00 | 2022 | |
| Amgen INC. | $18.75 | 2022 | |
| Foundation Medicine, INC. | $18.71 | 2023 | |
| Agios Pharmaceuticals, INC. | $16.31 | 2023 | Pyrukynd |
| Blueprint Medicines Corporation | $15.00 | 2022 | |
| Merck Sharp & Dohme LLC | $14.06 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.68 | 2022 | |
| G1 Therapeutics, INC. | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Talley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.